Price Target Revision
NeuroOne Medical Technologies (NasdaqCM:NMTC) recently underwent a price target upheaval as experts projected a surge to 3.21 / share, marking an impressive 18.20% leap from the previous estimate noted on January 16, 2024, which stood at 2.72. The revised figure emerges as an average derived from a spectrum of analyst projections, with the range varying between 3.18 and 3.31 / share. Such a recalibration signifies a formidable 200.28% escalation from the most recent closing price of 1.07 / share.
Fund Sentiment Analysis
Amid this fiscal fervor, 28 funds or institutions hold positions in NeuroOne Medical Technologies, a figure that has sustained constancy over the previous quarter. The average portfolio weight across all funds dedicated to NMTC now stands at 0.07%, reflecting a substantial 286.38% surge. In the sphere of institutional ownership, total shares have surged by 10.09% over the past quarter, amassing 3,023K shares. Notably, the current put/call ratio of NMTC at 0.00 denotes a prevailing bullish forecast.
Shareholder Landscape
Delving deeper into shareholder dynamics, Nantahala Capital Management, with a holding of 1,214K shares capturing 4.68% ownership, witnessed a minor divestment of 2.96% from their prior 1,250K share ownership bracket. On a brighter note, the organization boosted its NMTC portfolio allocation by a robust 20.63% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares retains 268K shares constituting 1.04% ownership, maintaining a stable position over the preceding quarter.
Geode Capital Management controls 197K shares, representing 0.76% ownership. The firm saw an ascendancy of 9.57% from their prior stake of 178K shares, marking a commendable 72.34% rise in portfolio allocation concerning NMTC.
Mayo Clinic maintains a stake in NMTC with 182K shares, encapsulating 0.70% ownership, a figure that remained unaffected in the prior quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares possesses 171K shares, securing 0.66% ownership. The entity experienced a slight uptick of 1.48% from their antecedent 168K shares while registering a 21.85% dip in portfolio allocation attributed to NMTC.
Background Insights
NeuroOne Medical Technologies Corporation specializes in film electrode technology, pivotal for diverse neurological applications spanning diagnosis through EEG recording, spinal cord stimulation, brain stimulation, and ablation solutions catering to individuals grappling with neurological disorders.
Fintel emerges as an eminent investing research platform catering to individual investors, traders, financial advisors, and minor hedge funds. The platform’s extensive dataset spans fundamentals, analyst reports, ownership and fund sentiment data, options sentiment, insightful insider trading trends, options flow, atypical options trades, and a plethora of other enriching facets. Furthermore, Fintel’s exclusive stock picks with a foundation in advanced, rigorously tested quantitative models are geared towards optimizing profitability.
Click to Learn More
This article was originally featured on Fintel.
The views and opinions articulated herein represent the author’s standpoint and do not necessarily align with those of Nasdaq, Inc.
